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Abstract
Background: The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for
first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen
(platinum/5-fluorouracil/cetuximab). This regimen has relatively high response and disease control rates but is
generally not curative and many patients will experience recurrent disease and/or metastasis. Therefore, there is a
great need to identify predictive biomarkers for recurrence and disease progression in cetuximab-treated HNSCC
patients to facilitate patient management and allow for treatment modification. The goal of this work is to assess
the potential of activating interleukin-1 (IL-1) ligands (IL-1 alpha [IL-1α], IL-1 beta [IL-1β]) as predictive biomarkers of
survival outcomes in HNSCC patients treated with cetuximab-based chemotherapy.
Methods: Baseline gene, serum and tumor expression of interleukin-1 (IL-1) ligands were analyzed from The Cancer
Genome Atlas (TCGA) database or clinical trials of cetuximab-based therapies and interrogated for associations with
clinical outcome data.
Results: High tumor gene expression of IL-1β was associated with a more favorable overall survival in
cetuximab-treated HNSCC patients but not in non-cetuximab-treated patients. In HNSCC patients treated with
cetuximab-based chemotherapy, higher gene and circulating levels of IL-1α and IL-1β were correlated with a
more favorable progression free survival compared to patients with low or undetectable levels of IL-1 ligands.
Conclusions: These findings suggest that IL-1 ligands may function as predictive biomarkers for tumor
response to cetuximab-based chemotherapy in HNSCC patients and warrants further investigation and
validation in larger clinical studies.
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Background
Cetuximab is a human/mouse chimeric antibody on an
IgG1 backbone that inhibits EGFR signaling by interfering
with the binding of EGFR ligands (EGF, TGFα) to EGFR
and also by the depletion of EGFR from the cell mem-
brane via receptor endocytosis [1]. In addition to cetuxi-
mab’s effects on EGFR, its IgG1 backbone triggers
additional antitumor activity in the form of natural killer
(NK) cell-mediated antibody-dependent cell-mediated
cytotoxicity (ADCC) [2–4]. Cetuximab-activated NK cells
are also able to promote dendritic cell (DC) maturation
and CD8+ T-cell activation [5] suggesting that cetuximab
can promote anti-tumor immunity in HNSCC patients.
Cetuximab is FDA approved for HNSCC treatment based
on its ability to increase survival in combination with radi-
ation for locally advanced disease [6] and improve re-
sponse rates in combination with chemotherapy (cisplatin
±5-FU) for R/M disease [7].
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To date, there are no biomarkers used in clinical prac-
tice that can predict tumor response to cetuximab in
HNSCC patients. Predictive biomarkers of tumor re-
sponse to EGFR inhibitors have been well established in
non-small cell lung cancer (NSCLC) [8] and colorectal
cancer (CRC) [9] but these mechanisms (including
EGFR and KRAS mutations) are extremely rare and are
not clinically relevant to HNSCC [10, 11]. Numerous
preclinical studies have identified potential predictive
biomarkers of EGFR inhibitor response in HNSCC in-
cluding alterations in EGFR ligand expression levels
[12–14], EGFR polymorphisms [15], EGFR variant III ex-
pression [16], nuclear EGFR [17], overexpression of
other ErbB family receptors [18], MET activation [19],
Axl overexpression [20], alterations in targets down-
stream of EGFR (e.g. PI3K, PTEN, src) [21] and FcγR
SNPs [22]. However, efforts to validate or target these
proposed mechanisms in clinical trials have yielded
modest results or have failed. Recent work has identified
a germline, functional single-nucleotide polymorphism
in the KRAS 3′-untranslated region (rs61764370) in 17%
of HNSCC patients which leads to gain of function
phenotype [23]. Interestingly, unlike activating KRAS
mutations in CRC, the presence of this “KRAS-variant”
was not found to be associated with resistance to cetuxi-
mab but rather favorable outcomes [23]. While these re-
sults are promising, it does not explain differences in
tumor response to cetuximab in the majority of HNSCC
patients lacking the KRAS variant. Altogether, it is clear
that further investigation is warranted to further identify
strategies that will predict and enhance tumor response
to cetuximab for R/M HNSCC patients given its import-
ance in standard of care.
Our previous work indicated that EGFR inhibition
triggers activation of the interleukin-1 (IL-1) pathway
[24, 25] although the clinical implications of this path-
way are unclear. The IL-1 pathway plays a central role in
immune and inflammatory responses by regulating the
expression of various inflammatory genes in immune
cells. This pathway is triggered when the ligands IL-1α
and IL-1β bind to the IL-1 receptor type 1 (IL-1R1) [26].
Upon ligand binding, the receptor forms a complex with
the IL-1 receptor accessory protein, leading to the re-
cruitment of MyD88, IL-1 receptor-associated kinases
and TRAF6 [26]. These signaling events prompt NFkB
and MAPK signaling leading to the expression of IL-1
target genes.
IL-1 signaling has been reported in various studies to be
associated with poor prognosis due to the resulting down-
stream expression of genes involved in tumor progression
[25, 27–31]. In contradiction to IL-1’s tumor-promoting
role, IL-1 signaling has been shown to be involved in
tumor cell killing via an anti-tumor immune response
[32–34]. IL-1 signaling is proposed as a key mediator of
host defense against malignancies mainly through its role
on NK cell activity (i.e. IFNγ production and ADCC) [32]
and NK-cell activity can be significantly inhibited by ana-
kinra (IL-1RA), or by neutralizing antibodies for IL-1 li-
gands [35]. IL-1 was shown to directly enhance survival of
CD4+ T cells and induce secondary CD8+ T cell responses
characterized by enhanced granzyme B expression and in-
creased IFNγ production [36–38].
Given that cetuximab’s anti-tumor activity is in part due
to natural killer (NK) and T cell-mediated cytotoxicity [1,
3, 39, 40] and IL-1 signaling can activate NK and T cell
anti-tumor immune responses [41–44], we propose that
increased tumor and/or circulating levels of IL-1 ligands
would be indicative of a strong anti-tumor immune re-
sponse leading to favorable and perhaps durable responses
to chemotherapy regimens that involve cetuximab. Here
we show preliminary evidence in limited cohorts of
HNSCC patients that higher gene and circulating levels of
IL-1α and IL-1β are correlated with favorable progression
free survival in HNSCC patients treated with cetuximab-
based chemotherapy compared to patients with low or un-
detectable levels of IL-1 ligands. These findings suggest
that IL-1 ligands may be promising as predictive bio-
markers for survival outcomes in cetuximab-based
chemotherapy-treated HNSCC patients.
Methods
Analysis of TCGA dataset
The Cancer Genome Browser (University of California –
Santa Cruz) was used to download a level 3 head and neck
cancer dataset (TCGA_HNSC_exp_HiSeqV2–2015-02-
24) from the Cancer Genome Atlas, along with corre-
sponding clinical data including treatment history. Only
HNSCC patients (n = 164) in the database where treat-
ment information was included were included in these
analyses. These patients were then separated into patients
that included cetuximab in their therapy regiment (n = 34)
and patients that did not include cetuximab in their ther-
apy regimen (n = 130) and ranked according to gene ex-
pression for each gene of interest in their tumors, with the
upper half denoted as “high gene x” and the lower half as
“low gene x”. None of these tumors were RAS mutants.
Kaplan-Meier survival curves were plotted comparing the
overall 3-year survival of patients with high or low tumor
expression of various genes. A subset of the patients in
the dataset (n = 42) also had gene expression analysis data
from adjacent normal tissue. For these patients, expres-
sion of IL-1 ligands was plotted for matched tumor vs.
normal tissue.
Patient tumor IL-1 gene expression analysis
Publically available global gene expression data from an
Illumina HumanHT-12_v4 expression beadchip array
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for R/M HNSCC patients treated with first-line cetuxi-
mab+chemotherapy (i.e. cisplatin, cisplatin+ 5-FU, cis-
platin+paclitaxel, cisplatin+pemetrexed) [45] was
analyzed. As described [45], patients with greater than 12
month progression free survival (PFS) were designated as
those with long PFS and patients with shorter than 5.6
months PFS were designated as those with short PFS. Log
transformed, pre-processed gene expression values in the
series matrix from GEO (GSE65021) were used for ana-
lysis. Differential expression analysis was performed be-
tween patients with long and short PFS using LIMMA
version 3.30.13 [45]. In this analysis, a single probe was
selected for each gene with the R/Bioconductor annota-
tion package IlluminaHumanv4.db version 1.26.0. Analysis
was performed on IL-1 ligands ((IL1A, ILMN_1658483;
IL1B, ILMN_775501) and reported p-values are false dis-
covery rate (FDR)-adjusted with Benjamini-Hotchberg on
unadjusted p-valued for this set of ligands.
Availability of data and material
Datasets from the TCGA (TCGA_HNSC_exp_HiSeqV2–
2015-02-24) and GEO databases (http://www.ncbi.nlm.
nih.gov/geo/, accession number GSE65021) are publi-
cally available. The datasets generated during and/or an-
alyzed during the current study are available from the
relevant authors on reasonable request.
Analysis of R/M HNSCC patient serum samples
Baseline serum samples from R/M HNSCC patients
scheduled for cetuximab-based chemotherapy (i.e. carbo-
platin, cisplatin, 5-FU, paclitaxel) at the University of Iowa
Hospitals and Clinics (UIHC) Holden Comprehensive
Cancer Center and R/M cetuximab-resistant HNSCC pa-
tients scheduled for cetuximab in combination with ficla-
tuzumab (human growth factor [HGF] antibody) in a
phase I study (ClinicalTrials.gov Identifier: NCT0342
2536) were collected. Serum IL-1 ligand (IL-1α, IL-1β)
levels were measured by enzyme-linked immunosorbent
assays (ELISAs). Both studies were approved by the re-
spective institution’s Institutional Review Board and was
conducted in accordance with ethical standards presented
in the 2013 Declaration of Helsinki. All subjects provided
their informed consent in written form for participation in
the study.
ELISAs on human serum/plasma
DuoSet ELISAs for IL-1α and IL-1β were purchased
from R&D Systems (Minneapolis, MN, USA) and carried
out according to manufacturer’s protocols. The lower
limits for detection were as follows: IL-1α – 7.8 pg/mL
and IL-1β - 3.9 pg/mL.
Flow cytometry
Normal human peripheral blood mononuclear cells
(PBMCs) were cultured at 10:1 and 1:1 effector/target ra-
tio for 6 h at 37 °C with SQ20B cells that were treated with
cetuximab with or without anakinra. Culture media con-
taining PBMCs were then stained with anti-CD3, anti-
CD16, anti-CD54 and anti-CD107a antibodies conjugated
to different fluorochromes. NK cells, gated on CD3− cells
in the lymphocyte FSC/SSC subset were analyzed for the
expression of CD16 (A) and CD54 (B) and CD107a (C).
Cells were collected on a FACSCanto flow cytometer. All
data were analyzed using FlowJo software.
Tumor cell implantation
Female athymic nu/nu (4–6weeks old) were purchased
from Envigo Laboratories (Huntingdon, Cambridgeshire,
United Kingdom). Mice were housed in a pathogen-free
barrier room in the Animal Care Facility at the University
of Iowa and handled using aseptic procedures. Mice were
allowed at least 3 days to acclimate prior to beginning ex-
perimentation, and food and water were made freely avail-
able. SQ20B (1 × 106 cells/mouse) were inoculated into
athymic nude mice by subcutaneous injection of 0.1mL ali-
quots of saline containing cancer cells into the right flank
using 26 gauge needles.
In vivo drug administration
Drug treatment commenced 3 days after tumor inoculation.
Female SQ20B tumor-bearing athymic nu/nu mice (n = 6
mice/treatment group) were randomized and treated either
an IL-1R antagonist (anakinra [ANA]) at 10mg/kg i.p. daily,
cetuximab (CTX) at 2mg/kg i.p. twice per week, or CTX+
ANA i.p. at the doses/schedules indicated above. Mice were
administered saline daily and 2mg/kg IgG i.p twice per
week as a control. All treatments were given for 3 weeks.
Mice were evaluated daily and tumor measurements and
weights were taken three times per week using Vernier cali-
pers. Tumor volumes were calculated using the formula:
tumor volume = (length × width2)/2. Mice were euthanized
via CO2 gas asphyxiation when tumor diameter exceeded
1.5 cm in any dimension. Tumor growth curves were plot-
ted over time and stopped after a mouse in any treatment
group reached euthanasia criteria.
Statistical analysis
Statistical analysis was carried out using GraphPad
Prism version 7 for Mac (GraphPad Software, La Jolla,
CA, USA). Differences in means between two groups
were determined by unpaired t-test. Kaplan-Meier sur-
vival curves were generated to illustrate the different
survival rates over time. Differences in survival were de-
termined by Log-rank (Mantel-Cox) test. For all experi-
ments, differences were considered significant if p < 0.05.
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Results
Tumor gene expression of IL-1 ligands may positively
predict survival in patients treated with cetuximab
RNA-sequencing data for HNSCC tumors and
matched normal tissue (n = 42) were analyzed from
the TCGA for mRNA levels of the IL-1 ligands IL-1α,
IL-1β and IL-1RA. IL1A and IL1B were found to be
significantly increased in tumors (Fig. 1a,b p < 0.0001
and p = 0.003, respectively) compared to normal sam-
ples while IL1RN (IL-1RA) was significantly decreased
in tumor versus normal tumors (Fig. 1c, p = 0.02).
RNA-sequencing data for HNSCC tumors (n = 164)
from the TCGA (with associated and complete clin-
ical outcome data) with high expression of IL-1 li-
gands were plotted for survival against low IL-1
ligand expressing tumors. Gene expression analyses
were performed on tumor specimens harvested before
treatment with chemotherapy or radiation. In patients
whose therapy did not include cetuximab (n = 34),
high gene levels of IL1A and IL1B were significantly
associated with worse survival compared to low gene
levels (Fig. 2a,b, p = 0.002 and 0.005, respectively).
On the other hand, in patients who were treated with
cetuximab-based therapy (n = 130), high IL1A and
IL1B gene levels were not associated with worse sur-
vival (Fig. 2d,e, p = 0.18 and 0.02, respectively). In
fact, IL1A and IL1B appeared to be associated with a
more favorable survival in cetuximab-based therapy-
treated patients although only the differences in IL1B
reached significance (Fig. 2e, p = 0.02). There was no
difference in survival outcomes for cetuximab- or
non-cetuximab-treated patients on the basis of IL1RN
tumor expression (Fig. 2c,f, p = 0.67 and 0.55, re-
spectively). Analysis of corresponding patient characteris-
tics and available clinicopathological data indicated no
differences between the cetuximab-based therapy versus
non-cetuximab-based therapy-treated patient cohorts on
the basis of sex, age, HPV status, treatment with radiother-
apy, or proportion of early/late stage cases (Table 1).
However, of the HNSCC patients analyzed, cetuximab-
based therapy was associated with a significantly higher
likelihood of relapse and a less complete treatment re-
sponses compared to non-cetuximab-based therapy (Table
1). Overall, these findings prompted the further evaluation
of IL1A and IL1B gene expression and their association
with survival outcomes in cetuximab-based therapy-
treated HNSCC patients.
Tumor gene expression of IL-1 ligands predict
progression-free survival (PFS) in patients treated with
cetuximab and chemotherapy
Gene expression of IL-1 ligands were retrospectively
determined from pre-treatment tumor biopsies from 40
R/M HNSCC patients who were treated with first-line
cetuximab-based chemotherapy [46]. In this published
study the authors separated the patients into those with
long PFS (> 12 months, median = 19 months, n = 14)
and short PFS (< 5.6 months, median = 3 months, n =
26) [46]. IL1A (Fig. 3a, FDR-adjusted p = 0.007) was sig-
nificantly higher in patients with long PFS compared to
short PFS, while IL1B trended higher in patients with
long PFS but fell short of statistical significance (Fig. 3b,
FDR-adjusted p = 0.059). There were no differences in
demographic or other clinicopathological parameters in
long PFS vs short PFS patients as already previously re-
ported [46]. Together, the results shown in Figs. 2 and
3 suggest a possible connection between IL-1 ligand ex-
pression and response to cetuximab-based therapy.
High serum IL-1 predicts progression-free survival in
HNSCC patients treated with cetuximab-containing
therapy
To determine if circulating IL-1 ligand levels would pre-
dict survival outcomes in cetuximab-based chemotherapy-
treated HNSCC patients we analyzed pre-treatment serum
samples from 11 consented patients who were treated
with cetuximab-based chemotherapy (i.e. carboplatin,
A CB
Fig. 1 Expression of IL-1 ligands is elevated in head and neck tumor versus normal tissue. Gene expression of IL1A (a), IL1B (b), and IL1RN (c) from
tumor (n = 42) and matched adjacent normal tissue was plotted for available HNSCC patients from the TCGA database
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cisplatin, 5-FU, paclitaxel) and have available and
complete clinical outcome data. IL-1 ligand levels varied
widely among the patients and ranged from undetectable
(0 pg/mL / below limit of detection) to 418 pg/mL (IL-1α)
and 262 pg/mL (IL-1β). Six out of the 11 patients had
undetectable baseline levels of IL-1 ligands. Differences
between pre-treatment IL-1 ligand levels in patients
with stable disease (SD, n = 6) compared to progressive
disease (PD, n = 5) according to RECIST criteria did not
meet significance (data not shown). None of the pa-
tients achieved a response of partial response (PR) or
complete response (CR). However, when PFS data was
analyzed there were significantly longer PFS times in
patients with detectable levels of IL-1α (Fig. 4a, p =
0.038, n = 5) and IL-1β (Fig. 4b, p = 0.037, n = 4) com-
pared to low IL-1 ligand levels using ELISA. These data
suggest that circulating IL-1 ligand levels may be prom-
ising as a predictive indicator of PFS rather than short-
term treatment response.
High serum IL-1 levels may predict survival outcomes in
cetuximab-resistant R/M HNSCC patients treated with
cetuximab+ficlatuzumab
We next determined if IL-1 ligand levels were associated
with survival outcomes in R/M HNSCC patients that
had previously progressed on cetuximab-based therapy
and were scheduled to receive cetuximab in combination
with the HGF monoclonal antibody ficlatuzumab [47] in
a phase I clinical trial (NCT02277197). Two patients
achieved PR, 6 achieved SD and 4 experienced PD. No
significant differences were observed in IL-1 ligand
levels between patients with SD, PD or PR (Fig. 5a,b).
There was also no significant difference in the survival
curves for the IL-1 ligands when analyzed by log-rank
test (Fig. 5c,d, p = 0.27 and 0.128 respectively). However,
a late divergence in the survival curves was observed for
both IL-1α (6 month survival = 38% [high] vs. 0% [low])
and IL-1β (6 month survival = 43% [high] vs. 0% [low])
which was associated with a delayed therapy benefit in
A B C
D E F
Fig. 2 Tumor gene expression of IL-1 ligands may positively predict survival in patients treated with cetuximab. Shown are Kaplan-Meier survival
curves comparing overall survival of HNSCC patients treated with “non-cetuximab based therapy” (No cetuximab) (n = 130 [a-c]) according to
with high (n = 64) or low (n = 66) IL1A (a), IL1B (b) and IL1RN (c) tumor gene expression; and HNSCC patients treated with “cetuximab based
therapy” (Cetuximab) (n = 34 [d-f]) according to with high (n = 18) or low (n = 16) IL1A (a), IL1B (b) and IL1RN (c) tumor gene expression
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patients with high circulating IL-1 ligand levels (Fig. 5c,d).
These data suggest that circulating IL-1 ligand levels may
be a predictive indicator of PFS in a subset of cetuximab-
refractory patients.
IL-1 blockade may reduce the anti-tumor efficacy of
cetuximab
In an effort to understand why PFS would be unfavorable
in cetuximab-based therapy-treated HNSCC patients with
low circulating IL-1 levels, we assessed NK cell activity
identified by CD3-CD56 + CD54+ cells (activated NK
cells) and CD3-CD53 + CD107a + (NK cell degranulation)
by flow cytometry after co-culture of PBMCs with cetuxi-
mab and cetuximab+anakinra-treated SQ20B cells. We
showed that IL-1 blockade using anakinra did not affect
cetuximab binding to the Fc gamma-receptor III (FcγRIII,
CD16) on NK cells (Fig. 6a) however, anakinra suppressed
NK cell activation induced by cetuximab (Fig. 6b) and NK
cell degranulation (Fig. 6c) when cultured at a 1:1 effector
to target ratio. These results suggest that IL-1 signaling
may be important for cetuximab-induced NK cell activity.
Lastly, we showed in SQ20B tumor-bearing athymic nude
mouse that anakinra (which binds both human and mouse
ligands) partially reversed the anti-tumor effect of cetuxi-
mab treatment (Fig. 7). These results suggest that low/re-
duced levels of IL-1 ligands may suppress the ability of
cetuximab to activate NK cell activity and thus reduce the
anti-tumor efficacy of this agent.
Altogether, our results indicate that higher tumor gene
expression and/or circulating levels of IL-1 ligands may be
associated with favorable survival outcomes in cetuximab-
based therapy-treated HNSCC patients. IL-1 ligands may
serve as promising predictive biomarkers for long-term re-
sponse to cetuximab-based therapy and warrants further
validation in much larger patient cohorts.
Table 1 HNSCC Patient Characteristics
Patient characteristics cetuximab
(n = 34)
% (n)
no cetuximab
(n = 130)
% (n)
p value
Male 71% (24) 83% (108) p = 0.10
Female 29% (10) 17% (22)
Mean age [range] 58.8 [35–82] 56.3 [19–80] p = 0.22
Stage at diagnosis
I, II 12% (4) 9% (12) p = 0.67
III, IV 88% (30) 90% (117)
Unknown 0% (0) 1% (1)
HPV status
Positive 15% (5) 18% (24) p = 0.85
Negative 26% (9) 26% (34)
Unknown 59% (20) 52% (70)
Relapsed
Yes 53% (18) 31% (40) p = 0.043
No 35% (12) 58% (75)
Unknown 12% (4) 12% (15)
Received radiation therapy
Yes 74% (25) 77% (100) p = 0.92
No 12% (4) 10% (13)
Unknown 15% (5) 13% (17)
Treatment best response
Complete response 26% (9) 42% (55) p = 0.004
Partial response 3% (1) 2% (3)
Stable disease 3% (1) 1% (1)
Progressive disease 21% (7) 3% (4)
Unknown 47% (16) 53% (69)
A B
Fig. 3 Tumor gene expression of IL-1 ligands predicts PFS in patients treated with cetuximab and chemotherapy. Comparison of pre-treatment
tumor gene expression of IL1A (a) and IL1B (b) in HNSCC patients treated with first-line cetuximab-based chemotherapy separated into long
progression free survival (PFS) (> 12 months, n = 14) and short PFS (< 5.6 months, n = 26)
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Discussion
The data from the limited cohorts presented here supports
the idea of IL-1 ligands as predictive biomarkers of favor-
able clinical outcomes specifically in cetuximab-treated R/
M HNSCC patients. IL-1 signaling is typically associated
with an aggressive/malignant phenotype, poor prognosis
and drug resistance in general [46, 48, 49]. Additionally,
published reports from the CANTOS trial suggested that
targeting IL-1β could reduce the incidence of lung cancer
and lung cancer mortality [50]. Our survival analyses from
the TCGA database showing high IL-1 ligand expression
being associated with worse survival in non-cetuximab-
treated HNSCC patients (Fig. 2a,b) supports the role of
IL-1 in poor prognosis. However our findings of acti-
vating IL-1 ligands being associated with more favor-
able survival outcomes in cetuximab-treated HNSCC
patients (Fig. 2d,e) challenge the current understanding of
the pro-survival role of IL-1 signaling in tumor biology.
The data set analyzed represents only the HNSCC patients
from the TCGA database that were accompanied by infor-
mation about their therapy regimen (Fig. 2). Therefore it is
possible that by selecting only these patients our dataset
may be biased. However the finding in this data set of a sig-
nificantly higher like-hood of relapse and a less complete
treatment response in cetuximab-treated HNSCC patients
compared to non-cetuximab-treated patients supports re-
sults from a recent phase 3 trial (RTOG 1016) showing
higher likelihood of locoregional failure and significantly
lower overall survival and progression free survival in
cetuximab-treated HNSCC patients compared to the non-
cetuximab treated patients. This suggests that our data set
may not be biased and perhaps may reflect realistic
BA
Fig. 4 High serum IL-1 may predict favorable PFS in HNSCC patients treated with cetuximab-containing therapy. Baseline serum samples from R/
M HNSCC patients scheduled for cetuximab-based chemotherapy were collected and serum levels of IL-1α (a) and IL-1β (b) levels were measured
by ELISA. Progression free survival was compared for patients with “detectable” versus “undetectable” serum levels of IL-1α (n = 5 vs n = 6
respectively) and IL-1β (n = 4 vs n = 7 respectively)
A B
Fig. 5 High serum IL-1 levels may predict survival outcomes in a subset of cetuximab-resistant R/M HNSCC patients treated with
cetuximab+ficlatuzumab. IL-1α (a) and IL-1β (b) levels were measured by ELISA in baseline serum samples from R/M cetuximab-resistant HNSCC
patients scheduled for cetuximab in combination with ficlatuzumab. Progression free survival was compared for patients with “high” versus “low”
serum levels of IL-1α (n = 8 vs n = 5 respectively) and IL-1β (n = 7 vs n = 6 respectively)
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outcomes of cetuximab therapy. IL-1 signaling has the cap-
ability of activating both NK and T cell anti-tumor immune
responses [33–35]. It is possible that this anti-tumor im-
munity role of IL-1 is beneficial for optimal anti-tumor effi-
cacy of cetuximab since NK cell-mediated ADCC and
CD8+ T cell activation are arguably the major mechanisms
of action of cetuximab [2, 3, 5]. Increased circulating levels
of activating IL-1 ligands would thus be indicative of a
strong anti-tumor immune response which would be pre-
dictive of a favorable and perhaps durable response to
cetuximab-based therapy.
Cetuximab is approved for first-line treatment of R/M
HNSCC as a part of the standard of care EXTREME regi-
men (cetuximab+platinum±5-fluorouracil) [51]. This regi-
men has relatively high response (36%) and disease (81%)
control rates but is generally not curative and many
patients will experience recurrent disease and/or metastasis.
Therefore, there is a great need to identify predictive
biomarkers for recurrence and disease progression in
cetuximab-treated R/M HNSCC patients to facilitate pa-
tient management and allow for treatment modification. In
R/M HNSCC patients treated with cetuximab-based
chemotherapy including the EXTREME regimen and
cetuximab+platinum+paclitaxel/pemetrexed, we show in-
creased gene expression of IL-1 ligands in baseline tumor
samples in patients with long PFS (> 12months) compared
to short PFS (< 5.6months) (Fig. 3). Note that in the EX-
TREME trial, the median PFS obtained with the EXTREME
regimen was 5.6months [51]. Therefore increased genetic
expression of IL-1 ligands may predict a favorable PFS in
patients treated with this regimen that is above and beyond
the median PFS reported in the EXTREME trial. These re-
sults are supported in a separate cohort of R/M HNSCC
patients that were treated with similar regimens described
Fig. 6 IL-1 blockade suppresses cetuximab-induced NK cell activity. Normal human peripheral blood mononuclear cells (PBMCs) were cultured at
10:1 and 1:1 effector/target ratio for 6 h at 37 °C with SQ20B cells that were treated with cetuximab with or without anakinra. Culture media
containing PBMCs were then stained with anti-CD3, anti-CD16, anti-CD54 and anti-CD107a antibodies conjugated to different fluorochromes. NK
cells, gated on CD3− cells in the lymphocyte FSC/SSC subset were analyzed for the expression of CD16 (a) and CD54 (b) and CD107a (c). Error
bars = SD, *:p < 0.05 vs cetuximab+anakinra
Fig. 7 Role of IL-1 pathway blockade on the anti-tumor efficacy of cetuximab. Female athymic (nu/nu) mice bearing SQ20B xenograft tumors
were treated with 2 mg/mouse cetuximab (CTX) twice/week i.p. with or without anakinra (IL-1RA) administered at 10 mg/kg daily i.p. for 3 weeks.
IgG and PBS were used as controls. N = 6 mice/treatment group. Error bars represent ± SEM. *p < 0.05 versus control; **p < 0.05 versus CTX
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in Fig. 4. In this case we show that high serum levels of acti-
vating IL-1 ligands were associated with favorable PFS com-
pared to low (Fig. 4c,d). These data support the tumor gene
expression results observed in Fig. 3 which is promising
since a serum biomarker would be ideal, as blood tests are
relatively non-invasive and inexpensive compared to gen-
etic analyses from tumor biopsies.
As mentioned before, PFS in the EXTREME trial was
quite short (median survival = 5.6months) and cetuxi-
mab-refractory R/M HNSCC patients have few remaining
therapy options. Therefore a number of clinical studies
have been carried out with the addition of experimental
agents to cetuximab therapy with the purpose of over-
coming resistance to cetuximab and increasing survival.
In a cetuximab-refractory R/M HNSCC patient cohort
treated with cetuximab and ficlatuzumab, we showed
that high baseline serum levels of IL-1 ligands were
associated with a more favorable PFS compared to low
serum levels (Fig. 5c,d). Although the differences in
PFS were not significant according to the conventional
log rank test used in assessing survival outcome differ-
ences, we did observe a late separation of the curves
(Fig. 5c,d) which is promising and typical of cancer
clinical trials utilizing immunotherapy agents that are
considered successful [52]. These results may indicate
even in cetuximab-refractory patients that IL-1 ligands
may still be associated with favorable/durable clinical
outcomes in a subset of patients treated with cetuxi-
mab-based therapies.
It is already well known that NK cell activity is a major
mechanism of action of cetuximab (in addition to EGFR
inhibition). The ability of IL-1 to predict favorable sur-
vival outcomes to cetuximab-based therapy may be due
to the role of IL-1 in mediating NK cell activity triggered
by cetuximab. It is possible that IL-1 signaling is neces-
sary for optimal cetuximab-induced NK cell activity and
anti-tumor efficacy which is supported by our data
showing that anakinra both suppresses number of acti-
vated NK cells induced by cetuximab (Fig. 6) and par-
tially (but significantly) reverses the anti-tumor efficacy
of cetuximab in athymic nude mice (Fig. 7) where NK
cells are present. These results represent a potential ex-
planation of why low gene or circulating IL-1 levels may
be associated with poor survival outcomes to cetuximab-
based therapy.
Altogether, we recognize that sample size is a major
limitation in all of these data sets analyzed in these
studies and our intention is not to draw concrete con-
clusions from this work. Our goal is to provide prelimin-
ary evidence from several different studies related to the
promising nature of IL-1 ligands as predictive bio-
markers of cetuximab response. Collectively, our results
suggest that IL-1 ligands are worthy of further investiga-
tion as predictive biomarkers of cetuximab response and
our future goals are to validate these findings in larger
clinical trials.
Conclusions
Here we provide preliminary evidence that tumor gene ex-
pression and/or circulating levels of activating IL-1 ligands
may be associated with HNSCC tumor response to cetuxi-
mab. While our results were obtained from small datasets,
the consistent and promising nature of our findings with
IL-1 ligand expression and response to the EXTREME
regimen and other cetuximab-based chemotherapy war-
rants further investigation into its potential use as a bio-
marker in a larger cohort of HNSCC patients treated with
cetuximab-based therapy. Beyond HNSCC, this work may
lay a foundation to study IL-1 ligands as biomarkers for
responsiveness to cetuximab in colorectal cancer and in
immune activating agents in other disease sites as well.
Overall, these results support the further investigation of
IL-1 ligands as predictive biomarkers for cetuximab re-
sponsiveness in HNSCC.
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